Aslan, CSI, NCIS deal

Aslan, CSI and NCIS partnered to develop ASLAN003 to treat hematologic cancers as monotherapy and in combination with other undisclosed agents. Aslan is developing the oral dihydroorotate dehydrogenase (DHODH) inhibitor to treat cancer, including acute myelogenous leukemia (AML) and solid tumors; the candidate has completed at least two Phase I studies. ...